FDA BPC-157 PCAC Research Update 2026
FDA BPC-157 2026 PCAC explainer: what peptide compounding review means for BPC-157, MOTS-c and TB-500 research.
Category Blog
WebberScience research updates cover catalog documentation, compound terminology, laboratory-model interpretation and changes affecting the research-material landscape. Articles separate mechanistic observations from clinical claims, identify the model being discussed and link readers to relevant product or research-guide pages. All materials are presented for laboratory research context only and are not intended for human or veterinary use.
Cagrilinitide Research Overview 2026
Cagrilinitide research overview: amylin analog mechanisms, comparisons with retatrutide and semaglutide, evidence limits, FAQ.
GLP-1 Parkinson’s Research Brief
Research note: This week’s strongest signal is GLP-1 neuroprotection research. A July 11 meta-analysis in Neurological Sciences reviewed glucagon-like peptide-1 receptor agonists in Parkinson’s disease research, adding momentum to the broader GLP-1 brain-health literature. Trending: GLP-1 and Parkinson’s Research The…
MOTS-c Weekly Research Brief
MOTS-c research trends, BPC-157 product highlight, and a study-design tip for peptide research interpretation.
MOTS-c Research Update: June 2026 Studies
MOTS-c research update for 2026: cardiac inflammation, metabolic signaling, evidence limits, and research-only FAQ.
Oral GLP-1 Research Notes
A concise Webber Science brief on oral GLP-1 research, peptide education resources, and careful research reading for Canadian women 40+.
GLP-3 (Ret) Research Update: GLP-1 Trends
Subject: GLP-3 (Ret) Research Update: GLP-1 Trends GLP-3 (Ret) continues to stand out as one of the most closely watched metabolic research compounds in the current peptide landscape. In recent trend monitoring, GLP-3 (Ret) showed strong year-over-year search growth and…
Are Peptides Legal Again? FDA Peptide Reclassification, BPC-157 Status & What Changed in 2026
On April 15, 2026, the FDA made one of the most significant regulatory moves in the peptide space in years: they removed 12 peptides — including BPC-157, TB-500, and Semax — from the Category 2 restricted substances list. If you’ve…
BPC-157 Side Effects: What the Research Says (FAQ)
A comprehensive research-based FAQ on BPC-157 side effects, covering what preclinical data shows, common questions from the research community, and important safety context.
BPC-157: Complete Guide for Canadian Researchers
Everything Canadian researchers need to know about BPC-157 (Body Protection Compound 157): mechanism of action, wellness applications, reconstitution, storage, safety considerations, and regulatory status in Canada.